- Companies
- Leadsynbio
Leadsynbio Funding, Investors & Competitors
Leadsynbio has raised $118M across 4 funding rounds, most recently a $67M undisclosed-stage round in September 2026.
Last Leadsynbio funding round
$67M
Undisclosed stage · Sep 2026
Cumulative funding Leadsynbio raised
$118M
across 4 funding rounds
Key investors in Leadsynbio
Lilly Asia Ventures
Sherpa Healthcare Partners
Caixin Capital
Caixin Industry Fund
Hillhouse Investment
Oriza Holdings
GL Ventures
CICC Capital
About Leadsynbio
Leadsynbio is a Suzhou Industrial Park-headquartered synthetic biology company recognized as a national Little Giant enterprise for specialized innovation. Established in 2015, it operates R&D centers in Suzhou and the United States alongside GMP-compliant manufacturing facilities in Hunan and Anhui provinces. The firm develops biosynthesis technologies via its proprietary platform, enabling large-scale production of core products for global customers. Leadsynbio integrates R&D, manufacturing, and supply chain capabilities to deliver high-efficiency biomanufacturing processes that cut costs and emissions for partners in multiple countries.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Leadsynbio Funding History
Leadsynbio has raised a total of $118M across 4 funding rounds.
Leadsynbio's first fundraising round was a $16M Series C in February 2022. The most recent completed round was a $67M undisclosed-stage round in September 2026.
Leadsynbio funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Sep 2026 | Undisclosed stage | Caixin Industry Fund; Jiangsu Industrial Investment Group; Suzhou Venture Capital; Caixin Capital; Maker Wisdom; Oriza Holdings | $67M | Suzhou Leadsynbio Technology Co., Ltd. completed a $67 million equity financing round in September 2026. Participants included Caixin Capital, Caixin Industry Fund, Jiangsu Industrial Investment Group, Maker Wisdom, Oriza Holdings, Suzhou Venture Capital, and Harvest Capital. |
| Jul 2025 | Series D | Jiashan Industrial; Caixin Capital; Hunan Xingxiang Investment; CICC Capital | $14M | - |
| Aug 2023 | Series D | Sherpa Healthcare Partners; Lilly Asia Ventures | $21M | Leadsynbio is a synthetic biology company based in Suzhou, China, with R&D centers in Suzhou Industrial Park and San Francisco, USA, and a production base in Changde, Hunan. It develops chemical and biological products for pharmaceuticals, health products, and agriculture using synthetic biology technology, supported by a platform and a team of over 100 people. The company has more than 20 products and focuses on commercialization, pipeline expansion, and green technology to support China's carbon goals. In early February (likely 2022 per source date), Leadsynbio completed a C-round financing exceeding RMB400 million, co-led by GL Ventures and Sherpa Healthcare Partners, with Asia Green Fund as a co-investor. Funds were allocated to accelerate commercialization of existing products, enhance the R&D pipeline, and expand the Hunan production base. A separate Series D round lists investors including Lilly Asia Ventures, Sherpa Healthcare Partners, New Hope Sichuan Venture Capital Fund, and U.S.-China Green Fund, with a last valuation of $313,650,000. |
| Feb 2022 | Series C | GL Ventures (lead); Lilly Asia Ventures (lead); Sherpa Healthcare Partners (lead); Caixin Industry Fund; New Hope Sichuan Venture Capital Fund; Asia Green Fund; Hillhouse Investment; U.S.-China Green Fund; GF Qianhe Investment | $16M | Leadsynbio is a synthetic biology company founded in 2015 and based in Suzhou, China, focused on research, development, production, and sales of industrial biotechnology products for pharmaceuticals, nutritional health care, and animal health. It employs genetic modification, metabolic modification, enzyme modification, fermentation modification, chemical synthesis, and high-throughput screening, with R&D centers in Suzhou Industrial Park and San Francisco, and production bases in Hunan and Anhui. In early February 2022, corresponding to approximately 08/02/2022, Leadsynbio completed its Series C-II financing round of over RMB400 million, co-led by GL Ventures and Sherpa Healthcare Partners, with participation from Asia Green Fund and other investors including Caixin Industry Fund, GF Qianhe Investment, Hillhouse Investment, Hillhouse Ventures, Lilly Asia Ventures, New Hope Sichuan Venture Capital Fund, and U.S.-China Green Fund. The funds were allocated to accelerate commercialization of existing products, improve the R&D pipeline, and expand the Hunan production base. The company has a comprehensive synthetic biology technology platform and a research and development team of more than 100 people, with over 20 products in its pipeline targeting pharmaceuticals, health products, and agricultural products. Leadsynbio aims to support China's carbon neutrality goals through innovative green technology. |
Who has invested in Leadsynbio?
17 investors have backed Leadsynbio across its funding rounds, including Lilly Asia Ventures, Sherpa Healthcare Partners, Caixin Capital, Caixin Industry Fund, Hillhouse Investment and Oriza Holdings.
Lead investors include GL Ventures, Lilly Asia Ventures and Sherpa Healthcare Partners.
Leadsynbio Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Feb 2022 | ||
| 2 | Participant | Jul 2025 | ||
| 2 | Lead | Feb 2022 | ||
| 2 | Lead | Feb 2022 | ||
| 1 | Participant | Jul 2025 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Feb 2022 | ||
| 1 | Participant | Feb 2022 | ||
| 1 | Lead | Feb 2022 | ||
| 1 | Participant | Feb 2022 | ||
| 1 | Participant | Feb 2022 | ||
| 1 | Participant | Sep 2026 | ||
This data is available for Pro users. Sign up to see all 17 Leadsynbio investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialLeadsynbio Competitors
Leadsynbio competitors include listed companies like Qinghai Salt Lake Industry, CF Industries, Industries Qatar and SABIC Agri-Nutrient, and private ones like Colossal Biosciences and Biobest.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $2.3B | $1.2B | $18B | 3.7x | ||
| Publicly listed | $7.1B | $3.2B | $17B | 2.7x | ||
| Publicly listed | $4.4B | $1.6B | $17B | 5.2x | ||
| Publicly listed | $3.5B | $1.4B | $15B | 3.8x | ||
| Private | - | - | $10B | - | ||
| Private | - | - | $1.5B | - |
Leadsynbio Public Comps
Leadsynbio is still privately-owned, but its public comps include Qinghai Salt Lake Industry, CF Industries, Industries Qatar, SABIC Agri-Nutrient, Zhejiang NHU, Fertiglobe, Cathay Biotech, PI Industries, K+S and Bloomage BioTechnology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | $1.2B | 6.1x | 3.7x | 11.9x | 6.0x | |||
| $7.1B | $3.2B | 3.0x | 2.7x | 6.7x | 5.7x | |||
| $4.4B | $1.6B | 3.5x | 5.2x | 9.6x | 23.5x | |||
| $3.5B | $1.4B | 3.4x | 3.8x | 8.5x | 11.9x | |||
| $3.3B | $1.5B | 3.5x | 3.0x | 7.6x | 6.7x | |||
| $2.8B | $1B | 2.2x | 1.8x | 6.2x | 5.4x | |||
| $494M | $116M | 7.3x | 6.3x | 31.3x | 24.5x | |||
| $709M | $203M | 3.4x | 3.3x | 12.0x | 14.3x | |||
This data is available for Pro users. Sign up to see all Leadsynbio competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Leadsynbio
| When was Leadsynbio founded? | Leadsynbio was founded in 2015. |
| Where is Leadsynbio headquartered? | Leadsynbio is headquartered in Suzhou, China. |
| Is Leadsynbio publicly listed? | No, Leadsynbio is a private, VC-backed company. |
| How much funding has Leadsynbio raised? | Leadsynbio has raised $118M across 4 funding rounds. |
| What was Leadsynbio's last funding round? | Leadsynbio's last funding round was a $67M undisclosed-stage round in September 2026. |
| Who are Leadsynbio's investors? | Leadsynbio's investors include Caixin Industry Fund, Caixin Capital, Sherpa Healthcare Partners, Lilly Asia Ventures, Jiashan Industrial, Jiangsu Industrial Investment Group, Suzhou Venture Capital, New Hope Sichuan Venture Capital Fund, Asia Green Fund, GL Ventures and 7 others. |
| Which companies are comparable to Leadsynbio? | Companies comparable to Leadsynbio include Qinghai Salt Lake Industry, CF Industries, Industries Qatar, SABIC Agri-Nutrient, Colossal Biosciences and Biobest. |
See companies similar to Leadsynbio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




